SCHEMBL14706398 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	SRC	P12931	9/20	0.51

▸	CYP1A2	P05177	2/20	0.43

▸	MEN1	O00255	1/20	0.43

▸	MAPK1	P28482	1/20	0.43

▸	KMT2A	Q03164	1/20	0.43

▸	TDP1	Q9NUW8	1/20	0.43

▸	EGFR	P00533	9/20	0.43

▸	BTK	Q06187	8/20	0.43

▸	LCK	P06239	6/20	0.43

▸	ITK	Q08881	4/20	0.43

▸	HDAC1	Q13547	5/20	0.43

▸	ABL1	P00519	3/20	0.42

▸	FYN	P06241	2/20	0.41

▸	YES1	P07947	2/20	0.41

▸	LYN	P07948	2/20	0.41

▸	FGR	P09769	2/20	0.41

▸	FRK	P42685	2/20	0.41

▸	DAPK3	O43293	1/20	0.41

▸	RIPK2	O43353	1/20	0.41

▸	HCK	P08631	1/20	0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL14706386	0.98	SRC (0.50)	SRCCYP1A2MEN1MAPK1KMT2A
SCHEMBL14706387	0.92	SRC (0.48)	SRCCYP1A2MEN1MAPK1KMT2A
SCHEMBL14693595	0.91	SRC (0.55)	SRCCYP1A2MEN1MAPK1KMT2A
SCHEMBL14693592	0.91	SRC (0.55)	SRCCYP1A2MEN1MAPK1KMT2A
SCHEMBL14693536	0.91	SRC (0.50)	SRCCYP1A2MEN1MAPK1KMT2A
SCHEMBL14693535	0.91	SRC (0.50)	SRCCYP1A2MEN1MAPK1KMT2A
SCHEMBL18380714	0.90	SRC (0.45)	SRCCYP1A2MEN1MAPK1KMT2A
SCHEMBL18380715	0.89	SRC (0.44)	SRCCYP1A2MEN1MAPK1KMT2A
SCHEMBL15087015	0.89	SRC (0.41)	SRCCYP1A2MEN1MAPK1KMT2A
SCHEMBL14575421	0.89	BTK (0.57)	EGFRBTKLCKITKLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9546172-B2	Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors	PHARMACYCLICS LLC (US)	2017-01-17	—	—	US	disclosed
US-9546172-B2	Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors	PHARMACYCLICS LLC (US)	2017-01-17	—	—	US	disclosed
US-9273051-B2	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors	PHARMACYCLICS LLC (US)	2016-03-01	—	—	US	disclosed
US-9273051-B2	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors	PHARMACYCLICS LLC (US)	2016-03-01	—	—	US	disclosed
US-20130172314-A1	PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS	PHARMACYCLICS, INC. (US)	2013-07-04	—	—	US	disclosed
US-20130172314-A1	PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS	PHARMACYCLICS, INC. (US)	2013-07-04	—	—	US	disclosed
US-8377946-B1	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors	PHARMACYCLICS, INC. (US)	2013-02-19	—	—	US	disclosed
US-8377946-B1	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors	PHARMACYCLICS, INC. (US)	2013-02-19	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20130172314-A1	PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS	BTK, LCK, LYN	SRC 43/4885CYP1A2 3563/4885MEN1 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.